Media store

Media Releases

Published on: 22 October 2021

FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo™ (ranibizumab injection) 100 mg/mL for ...

Published on: 22 October 2021

Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)

Basel, 22 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer ...

Published on: 20 October 2021

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months – outlook for 2021 raised

CEO Severin Schwan on the results: “The demand for coronavirus tests remained high in the third quarter due to the Delta variant.

Upcoming Events

All

Media contacts

For media requests

+41 61 688 8888

Media Relations Team

For all general enquiries

Please call the Roche switchboard on
Phone:+41 61 688 11 11